Abstract: JavaScript has significantly evolved, broadening its capabilities. However, the uptake of tail call optimization (TCO) remains limited, largely due to concerns about debugging difficulties ...

Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Najat Khan: Good morning, and thank you so much for joining us. I want to start by briefly framing where Recursion Pharmaceuticals, Inc. is today in its journey and evolution. Over the past decade, ...

Recursion Pharmaceuticals Inc. (RXRX) reported its third-quarter 2025 earnings, revealing a mixed performance with an EPS of -$0.36, slightly surpassing the forecast of -$0.37. However, the company ...

Recursion narrowly beat EPS expectations, signaling effective cost management. Revenue fell short by 69.44%, raising concerns about growth prospects. The company maintains a strong cash position with ...

Earnings call Recursion ended Q3 2025 with $785M in cash and no financing needs through 2027, aided by a 35% expense reduction and $40M in partnership inflows YTD. A $30M milestone from Roche ...